Journal Scans
Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer
Cost-Effectiveness of Trastuzumab in HER2-Positive Metastatic Breast Cancer
C Perez-Ellis, A Goncalves, J Jacquemier, M Marty, V Girre, H Roché, E Brain, J-P Moatti, P Viens, A-G Le Corroller-Soriano
20090901
2009 Oct 1
Am J Clin Oncol
Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer
Am J Clin Oncol. 2009 Oct 1;32(5):492-497, C Perez-Ellis, A Goncalves, J Jacquemier, M Marty, V Girre, H Roché, E Brain, J-P Moatti, P Viens, A-G Le Corroller-Soriano
TAKE-HOME MESSAGE
Abstract
Abstract
Objective: In women with Human Epidermal growth Receptor 2 (HER2)-positive metastatic breast cancer (MBC), Trastuzumab has become the standard of care but previous studies have raised doubts about its economic acceptability. We carried out the first cost-effectiveness study for Trastuzumab in MBC patients, in France, that is based on observed resource use and outcomes in clinical practice. Methods: We retrospectively analyzed 47 HER2-positive MBC patients in a before-and-after design study. Nineteen...
